This segment focuses on the research, development, and clinical trials of ORMD-0801, an oral insulin capsule, for the treatment of diabetes. Research and development activities include formulation optimization, preclinical studies, and Phase II and Phase III clinical trials to assess efficacy and safety. The technology utilizes a proprietary oral delivery platform to protect insulin from degradation in the gastrointestinal tract, enabling effective absorption. The therapeutic area is diabetes, specifically targeting both Type 1 and Type 2 diabetes patients. The patient impact is significant, offering a potential alternative to injectable insulin, improving patient adherence and quality of life. Market positioning is as a pioneer in oral insulin, with a competitive advantage in its unique delivery technology. Future opportunities include expanding the product line to include combination therapies and exploring applications in other metabolic disorders. Regulatory and clinical aspects involve navigating FDA approval processes and conducting rigorous clinical trials. Partnerships and collaborations are crucial for manufacturing, distribution, and commercialization, as demonstrated by the joint venture with Hefei Tianhui Biotech Co., Ltd.

This segment is dedicated to the development of ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) analog capsule, for the treatment of type 2 diabetes and potential weight loss applications. Research and development efforts include formulation, preclinical studies, and Phase I clinical trials to evaluate safety and efficacy. The technology leverages Oramed's oral delivery platform to protect the GLP-1 analog from degradation, enabling oral administration. The therapeutic area is type 2 diabetes, with potential applications in weight management. The patient impact is aimed at providing an oral alternative to injectable GLP-1 receptor agonists, improving patient convenience and adherence. Market positioning is focused on capturing a share of the growing market for GLP-1-based therapies. Future opportunities include expanding the product pipeline and exploring combination therapies. Regulatory and clinical aspects involve clinical trials and regulatory submissions. Partnerships and collaborations are essential for manufacturing, distribution, and commercialization.

This segment focuses on the development of an oral leptin capsule for weight loss. Research and development activities include formulation, preclinical studies, and clinical trials to assess the efficacy and safety of the oral leptin capsule. The technology utilizes Oramed's oral delivery platform to protect leptin from degradation in the gastrointestinal tract, enabling effective absorption. The therapeutic area is weight management, targeting individuals struggling with obesity. The patient impact is significant, offering a potential oral treatment option for weight loss, improving patient adherence and quality of life. Market positioning is focused on capturing a share of the growing weight loss market. Future opportunities include exploring combination therapies and expanding the product pipeline. Regulatory and clinical aspects involve navigating FDA approval processes and conducting rigorous clinical trials. Partnerships and collaborations are crucial for manufacturing, distribution, and commercialization.